The Therapeutic and Prognostic Implications of Tumor Immune Microenvironment in The Neoadjuvant Immunotherapy Combined With Chemoradiotherapy for Rectal Cancer
Latest Information Update: 10 Jul 2026
At a glance
- Drugs Capecitabine (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms TIMENT-R
Most Recent Events
- 07 Jul 2026 Status changed from not yet recruiting to active, no longer recruiting.
- 16 Sep 2022 Planned initiation date changed from 20 Aug 2022 to 20 Sep 2022.
- 23 Aug 2022 New trial record